Development of humoral and cellular immune response in infants after pneumococcal conjugate vaccinations with Synflorix or Prevenar-13.

Trial Profile

Development of humoral and cellular immune response in infants after pneumococcal conjugate vaccinations with Synflorix or Prevenar-13.

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Pneumococcal infections
  • Focus Pharmacodynamics
  • Acronyms PIEN
  • Most Recent Events

    • 25 Apr 2017 Results (n=890) assessing differences in immune responses to PCV13 and PCV10 using patient data from NCT01204658, NCT01616459 and NTR3069 trials, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
    • 17 Aug 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2011-002103-15).
    • 17 Aug 2013 Status changed from planning to completed as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top